MX2019000898A - Amortiguador de lavado de cromatografia de afinidad. - Google Patents
Amortiguador de lavado de cromatografia de afinidad.Info
- Publication number
- MX2019000898A MX2019000898A MX2019000898A MX2019000898A MX2019000898A MX 2019000898 A MX2019000898 A MX 2019000898A MX 2019000898 A MX2019000898 A MX 2019000898A MX 2019000898 A MX2019000898 A MX 2019000898A MX 2019000898 A MX2019000898 A MX 2019000898A
- Authority
- MX
- Mexico
- Prior art keywords
- wash buffer
- less
- affinity chromatography
- interest
- protein
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
- B01D15/426—Specific type of solvent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un amortiguador de lavado que comprende arginina en una concentración mayor que 0 mM y menor que alrededor de 500 mM, guanidina en una concentración mayor que 0 mM y menor que alrededor de 250 mM, cloruro de sodio en una concentración mayor que 0 mM y menor que alrededor de 250 mM y un tensioactivo aniónico en una concentración mayor que 0 mM y menor que alrededor de 50 mM, o tensioactivo no iónico en una concentración mayor que 0 % y menor que alrededor de 0.25 %. Cuando se utiliza durante una purificación por cromatografía de afinidad de una proteína de interés, tal como un anticuerpo, el amortiguador de lavado reduce de manera significativa el nivel de proteínas de célula hospedadora de la preparación. Después de la cromatografía de afinidad con el amortiguador de lavado, la proteína de interés puede purificarse adicionalmente mediante el uso de cromatografía de membrana.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366302P | 2016-07-25 | 2016-07-25 | |
| US201662366309P | 2016-07-25 | 2016-07-25 | |
| US201762523032P | 2017-06-21 | 2017-06-21 | |
| PCT/US2017/043743 WO2018022628A1 (en) | 2016-07-25 | 2017-07-25 | Affinity chromatography wash buffer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000898A true MX2019000898A (es) | 2019-07-01 |
Family
ID=60989729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000898A MX2019000898A (es) | 2016-07-25 | 2017-07-25 | Amortiguador de lavado de cromatografia de afinidad. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10688412B2 (es) |
| EP (1) | EP3487868A4 (es) |
| JP (1) | JP7187436B2 (es) |
| KR (1) | KR102359192B1 (es) |
| CA (1) | CA3031028C (es) |
| IL (1) | IL264123B (es) |
| MX (1) | MX2019000898A (es) |
| WO (1) | WO2018022628A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| EP2978440B1 (en) | 2013-03-27 | 2019-10-02 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a and diagnosing fibrosis by detecting il31ra |
| US10316083B2 (en) | 2013-07-19 | 2019-06-11 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
| EP3430172A4 (en) | 2016-03-17 | 2019-08-21 | Cedars-Sinai Medical Center | METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2 |
| US10322174B2 (en) | 2016-10-26 | 2019-06-18 | Cedars-Sinai Medical Center | Neutralizing anti-TL1A monoclonal antibodies |
| WO2018237159A1 (en) | 2017-06-21 | 2018-12-27 | Cephalon, Inc. | WASH PAD FOR CATIONIC EXCHANGE CHROMATOGRAPHY |
| EP3784699A4 (en) | 2018-04-25 | 2022-04-13 | Prometheus Biosciences, Inc. | OPTIMIZED ANTI-TL1A ANTIBODIES |
| KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
| WO2021147857A1 (en) * | 2020-01-20 | 2021-07-29 | Wuxi Biologics (Shanghai) Co., Ltd | A novel wash buffer solution for affinity chromatography |
| IL296634A (en) * | 2020-04-09 | 2022-11-01 | Cytomx Therapeutics Inc | Preparations containing activatable antibodies |
| JP2023523324A (ja) * | 2020-04-27 | 2023-06-02 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗体のプロテインａクロマトグラフィー精製 |
| CN112827217A (zh) * | 2020-12-29 | 2021-05-25 | 苏州良辰生物医药科技有限公司 | 一种层析柱清洗液及其应用 |
| CN116236819B (zh) * | 2023-05-09 | 2023-08-04 | 成都佩德生物医药有限公司 | 一种批量纯化多肽毒素的方法及复合型双层层析柱 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4672044A (en) | 1984-08-24 | 1987-06-09 | Scripps Clinic & Research Foundation | Murine monoclonal antibody combining site to human C3b receptor (CR1) |
| JPH01238534A (ja) | 1988-03-17 | 1989-09-22 | Mitsui Toatsu Chem Inc | エンドトキシンの除去方法 |
| AU633007B2 (en) * | 1988-06-14 | 1993-01-21 | Cell-Sci Corporation | Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same |
| GB9022547D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
| GB0304576D0 (en) | 2003-02-28 | 2003-04-02 | Lonza Biologics Plc | Protein a chromatography |
| JPWO2004087761A1 (ja) | 2003-03-31 | 2006-07-27 | 麒麟麦酒株式会社 | ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製 |
| US20050255560A1 (en) | 2003-11-21 | 2005-11-17 | Zeren Gao | Ztnf11, a tumor necrosis factor |
| US8084032B2 (en) | 2004-01-21 | 2011-12-27 | Ajinomoto Co., Inc. | Purification method which prevents denaturation of an antibody |
| CA2577329A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| AU2005279347A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| KR101482791B1 (ko) | 2005-03-11 | 2015-01-21 | 와이어쓰 엘엘씨 | 약한 분배성 크로마토그래피법 |
| PL2380592T3 (pl) * | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals International Gmbh | Przeciwciało antagonistyczne skierowane przeciwko peptydowi powiązanemu z genem kalcytoniny |
| JP5530633B2 (ja) | 2006-01-06 | 2014-06-25 | イー・エム・デイー・ミリポア・コーポレイシヨン | アフィニティークロマトグラフィーマトリックスおよびその作成および使用法。 |
| US7714111B2 (en) * | 2006-09-08 | 2010-05-11 | Wyeth Llc | Arginine derivative wash in protein purification using affinity chromatography |
| CN101848926B (zh) | 2007-08-21 | 2014-04-30 | 越智隆弘 | 能够结合免疫球蛋白的肽 |
| US20090162372A1 (en) | 2007-11-30 | 2009-06-25 | Medarex, Inc. | Fibronectin ed-b antibodies, conjugates thereof, and methods of use |
| JP5504579B2 (ja) | 2008-05-12 | 2014-05-28 | 積水ハウス株式会社 | 住宅の床着脱構造及び住宅の改装方法 |
| WO2009149067A1 (en) | 2008-06-03 | 2009-12-10 | Patrys Limited | Process for purification of antibodies |
| FI3750552T3 (fi) | 2008-08-14 | 2023-07-25 | Acceleron Pharma Inc | Gdf-loukkuja |
| AU2009282234A1 (en) | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
| EP2346900A1 (en) | 2008-10-29 | 2011-07-27 | Wyeth LLC | Methods for purification of single domain antigen binding molecules |
| WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
| EP2360183B1 (en) | 2008-12-19 | 2016-07-27 | Takeda Pharmaceutical Company Limited | Antibody purification method by mixed mode chromatography utilizing an arginine-containing loading solution |
| KR20120007492A (ko) | 2009-01-23 | 2012-01-20 | 가부시키가이샤 엠엠티 | 이뮤노글로불린 결합능을 갖는 펩티드 |
| EP2513134B1 (en) * | 2009-12-18 | 2017-09-06 | Novartis AG | Wash solution and method for affinity chromatography |
| EP2583973B1 (en) | 2010-06-21 | 2018-03-21 | Kyowa Hakko Kirin Co., Ltd. | Method for purifying protein using amino acid |
| BR122020013379B1 (pt) * | 2011-09-30 | 2023-01-03 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos contra tl1a e seus usos |
| PL3677591T3 (pl) * | 2013-04-29 | 2023-06-26 | Teva Pharmaceuticals Australia Pty Ltd | Przeciwciała anty-cd38 i fuzje z interferonem alfa-2b o osłabionej aktywności |
| EP3683232A1 (en) * | 2013-09-13 | 2020-07-22 | F. Hoffmann-La Roche AG | Methods and compositions comprising purified recombinant polypeptides |
| WO2018170488A1 (en) | 2017-03-17 | 2018-09-20 | Gilead Sciences, Inc. | Method of purifying an antibody |
| WO2018237159A1 (en) * | 2017-06-21 | 2018-12-27 | Cephalon, Inc. | WASH PAD FOR CATIONIC EXCHANGE CHROMATOGRAPHY |
-
2017
- 2017-07-25 JP JP2019503524A patent/JP7187436B2/ja active Active
- 2017-07-25 US US15/659,093 patent/US10688412B2/en active Active
- 2017-07-25 EP EP17835124.3A patent/EP3487868A4/en active Pending
- 2017-07-25 MX MX2019000898A patent/MX2019000898A/es unknown
- 2017-07-25 WO PCT/US2017/043743 patent/WO2018022628A1/en unknown
- 2017-07-25 KR KR1020197002710A patent/KR102359192B1/ko active IP Right Grant
- 2017-07-25 CA CA3031028A patent/CA3031028C/en active Active
-
2019
- 2019-01-07 IL IL264123A patent/IL264123B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3487868A4 (en) | 2020-07-29 |
| KR102359192B1 (ko) | 2022-02-04 |
| JP2019525925A (ja) | 2019-09-12 |
| US20180021696A1 (en) | 2018-01-25 |
| CA3031028A1 (en) | 2018-02-01 |
| KR20190032394A (ko) | 2019-03-27 |
| IL264123A (en) | 2019-02-28 |
| IL264123B (en) | 2021-03-25 |
| WO2018022628A1 (en) | 2018-02-01 |
| CA3031028C (en) | 2024-02-13 |
| EP3487868A1 (en) | 2019-05-29 |
| JP7187436B2 (ja) | 2022-12-12 |
| US10688412B2 (en) | 2020-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000898A (es) | Amortiguador de lavado de cromatografia de afinidad. | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
| EA201892671A1 (ru) | Пегилированный свиной интерферон и способы его применения | |
| EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
| AU2016262093A8 (en) | Enhancing endonuclease based gene editing in primary cells | |
| WO2019035880A8 (en) | EXOSOMES OF PURIFIED MESENCHYMAL STEM CELLS AND USES THEREOF | |
| BR112017015567A2 (pt) | proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica | |
| BR112017008106A2 (pt) | polipeptídeo de ligação a fc, multímero, ácido nucleico ou vetor, sistema de expressão, matriz de separação, e, método para isolar uma imunoglobina. | |
| SG10201900661YA (en) | Purification platform for bispecific antibodies | |
| SG10201908027QA (en) | Use of alkaline washes during chromatography to remove impurities | |
| MX2018002068A (es) | Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes. | |
| MX2021003475A (es) | Metodos de purificacion de proteinas. | |
| MX2016017115A (es) | Metodos y reactivos para la purificacion de proteinas. | |
| EP3543335A3 (en) | Soluble intein fusion proteins and methods for purifying biomolecules | |
| WO2017046391A3 (en) | Process of manufacture of annexin v | |
| MX2023014077A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| MX2018001536A (es) | Metodo para la reduccion de proteinas de celulas hospederas en cromatografia de afinidad. | |
| WO2016130628A8 (en) | Griffithsin mutants | |
| WO2019014260A3 (en) | BLOOD COMPONENT POTENTIATION OF ANTIBACTERIAL ACTIVITY OF THE LYTIC PROTEIN AND METHODS AND USES THEREOF | |
| MX2017008410A (es) | Reduccion selectiva de residuos cisteina en anticuerpos il-17. | |
| PH12017502323A1 (en) | Novel xylanase | |
| MX2020006586A (es) | Metodos para potenciar la eliminacion de impurezas durante una cromatografia con proteina a. | |
| MY197491A (en) | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof | |
| EA201790241A1 (ru) | Эффективная селективность в отношении рекомбинантных белков |